

FILE 'HOME' ENTERED AT 12:03:51 ON 28 AUG 2005

09/963,858

=> file biosis medline caplus wpids uspatfull  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	0.21	0.21

FILE 'BIOSIS' ENTERED AT 12:04:31 ON 28 AUG 2005  
Copyright (c) 2005 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 12:04:31 ON 28 AUG 2005

FILE 'CAPLUS' ENTERED AT 12:04:31 ON 28 AUG 2005.  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 12:04:31 ON 28 AUG 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 12:04:31 ON 28 AUG 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

\*\*\* YOU HAVE NEW MAIL \*\*\*

=> s dendrimer  
L1 10363 DENDRIMER

=> s l1 and urea  
L2 479 L1 AND UREA

=> s l2 and side product?  
L3 16 L2 AND SIDE PRODUCT?

=> dup rem l3  
PROCESSING COMPLETED FOR L3  
L4 16 DUP REM L3 (0 DUPLICATES REMOVED)

=> d l4 bib abs 1-16

L4 ANSWER 1 OF 16 USPATFULL on STN  
AN 2005:165902 USPATFULL  
TI Amphiphilic [5:1]- and [3:3]- hexakisadducts of fullerenes  
IN Hirsch, Andreas, Rathsberg, GERMANY, FEDERAL REPUBLIC OF  
PI US 2005143327 A1 20050630  
AI US 2004-963990 A1 20041013 (10)  
PRAI US 2003-511763P 20031015 (60)  
DT Utility  
FS APPLICATION  
LREP WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON,  
TX, 77042, US  
CLMN Number of Claims: 23  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Page(s)  
LN.CNT 2221

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Herein are disclosed substituted fullerenes, comprising a fullerene core (C<sub>n</sub>), wherein n is an even integer greater than or equal to 60; 3 or 5 dihydrocarbylmalonate (>C(COOR<sup>1</sup>)(COOR<sup>2</sup>)) groups bonded to the fullerene core; and 1 or 3 polar extended malonate groups (>C(COOR<sup>3</sup>)(COOR<sup>4</sup>)) bonded to the fullerene core. The substituted fullerenes can form micelles, and can be used to ameliorate oxidative stress diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 16 USPATFULL on STN

AN 2005:23972 USPATFULL  
TI In vivo gene silencing by chemically modified and stable siRNA  
IN Rana, Tariq M., Shrewsbury, MA, UNITED STATES  
PA UNIVERSITY OF MASSACHUSETTS, Worcester, MA (U.S. corporation)  
PI US 2005020521 A1 20050127  
AI US 2003-672069 A1 20030925 (10)  
PRAI US 2002-413529P 20020925 (60)  
US 2002-426982P 20021115 (60)  
US 2003-458051P 20030326 (60)  
US 2003-493095P 20030805 (60)

DT Utility  
FS APPLICATION  
LREP LAHIVE & COCKFIELD, LLP., 28 STATE STREET, BOSTON, MA, 02109  
CLMN Number of Claims: 83  
ECL Exemplary Claim: 1  
DRWN 42 Drawing Page(s)  
LN.CNT 5638

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions for RNA interference and methods of use thereof. In particular, the invention provides small interfering RNAs (siRNAs) having modification that enhance the stability of the siRNA without a concomitant loss in the ability of the siRNA to participate in RNA interference (RNAi). The invention also provides siRNAs having modification that increase targeting efficiency. Modifications include chemical crosslinking between the two complementary strands of an siRNA and chemical modification of a 3' terminus of a strand of an siRNA. Preferred modifications are internal modifications, for example, sugar modification, nucleobase modification and/or backbone modifications. Such modifications are also useful, e.g., to improve uptake of the siRNA by a cell. Functional and genomic and proteomic methods are featured. Therapeutic methods are also featured.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 16 USPATFULL on STN  
AN 2005:17501 USPATFULL  
TI Thiol selective water soluble polymer derivatives  
IN Kozlowski, Antoni, Huntsville, AL, UNITED STATES  
Gross, Remy F., III, Huntsville, AL, UNITED STATES  
McManus, Samuel P., Brevard, NC, UNITED STATES  
PI US 2005014903 A1 20050120  
AI US 2004-753047 A1 20040106 (10)  
PRAI US 2003-438555P 20030106 (60)  
US 2003-455084P 20030314 (60)  
DT Utility  
FS APPLICATION  
LREP NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070  
CLMN Number of Claims: 63  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2474

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides water-soluble, polymer derivatives having a thiol-selective terminus suitable for selective coupling to thiol groups, such as those contained in the cysteine residues of proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 16 USPATFULL on STN  
AN 2004:300145 USPATFULL  
TI Segmented polymers and their conjugates  
IN Kozlowski, Antoni, Huntsville, AL, UNITED STATES  
Shen, Xiaoming, Madison, AL, UNITED STATES  
Bentley, Michael D., Huntsville, AL, UNITED STATES  
Fang, Zhihao, Madison, AL, UNITED STATES  
Sander, Tony L., Madison, AL, UNITED STATES  
PI US 2004236015 A1 20041125  
AI US 2003-734858 A1 20031211 (10)

RLI Continuation-in-part of Ser. No. US 2001-24357, filed on 18 Dec 2001,

GRANTED, Pat. No. US 6774180

PRAI · US 2000-256801P 20001218 (60)

DT Utility

FS APPLICATION

LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026

CLMN Number of Claims: 45

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2745

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Segmented water soluble polymers, containing a higher molecular weight segment linked to a lower molecular weight segment, are described. In one embodiment, the polymer segments are poly(ethylene glycol) segments. The segmented polymers are functionalized and are useful for conjugation to various moieties such as pharmacologically active substances. Also described are conjugates of such polymers and methods of their preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 16 USPATFULL on STN

AN 2004:262046 USPATFULL

TI Hydrolytically stable maleimide-terminated polymers

IN Kozlowski, Antoni, Huntsville, AL, UNITED STATES

Gross, Remy F., III, Huntsville, AL, UNITED STATES

McManus, Samuel P., Brevard, NC, UNITED STATES

PI US 2004204548 A1 20041014

AI US 2003-751274 A1 20031231 (10)

PRAI US 2002-437211P 20021231 (60)

DT Utility

FS APPLICATION

LREP NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070

CLMN Number of Claims: 130

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 3229

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to hydrolytically stabilized maleimide-functionalized water soluble polymers and to methods for making and utilizing such polymers and their precursors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 16 USPATFULL on STN

AN 2004:152427 USPATFULL

TI Water-soluble polymer alkanals

IN Kozlowski, Antoni, Huntsville, AL, UNITED STATES

PI US 2004116649 A1 20040617

AI US 2003-659734 A1 20030909 (10)

PRAI US 2002-409251P 20020909 (60)

US 2003-456850P 20030321 (60)

DT Utility

FS APPLICATION

LREP NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070

CLMN Number of Claims: 154

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 3618

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to alkanal derivatives of water-soluble polymers such as poly(ethylene glycol), their corresponding hydrates and acetals, and to methods for preparing and using such polymer alkanals. The polymer alkanals of the invention are prepared in high purity and exhibit storage stability.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 16 USPATFULL on STN  
AN 2004:141219 USPATFULL  
TI · Multiple methoxyoxalamido and succinimido precursors for nucleophilic addition  
IN Polouchine, Nikolai N., Montgomery Village, MD, United States  
PA Fidelity Systems, Inc., Gaithersburg, MD, United States (U.S. corporation)  
PI US 6747142 B1 20040608  
AI US 2000-655316 20000905 (9)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Fredman, Jeffrey; Assistant Examiner: Chunduru, Suryapraba  
LREP Oliff & Berridge, PLC  
CLMN Number of Claims: 37  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 1164  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds and the synthesis of compounds containing multiple precursor groups and allowing the efficient synthesis of highly functionalized oligonucleotides and oligomers are provided. Also, a branching unit that helps to further increase the density of functional groups on synthetic oligonucleotides and oligomers is provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 16 USPATFULL on STN  
AN 2003:207869 USPATFULL  
TI Peptide-enhanced transfections  
IN Hawley-Nelson, Pamela, Silver Spring, MD, UNITED STATES  
Lan, Jianqing, Germantown, MD, UNITED STATES  
Shih, PoJen, Columbia, MD, UNITED STATES  
Jessee, Joel A., Mt. Airy, MD, UNITED STATES  
Schifferli, Kevin P., Germantown, MD, UNITED STATES  
Gebeyehu, Gulilat, Silver Spring, MD, UNITED STATES  
Ciccarone, Valentina C., Gaithersburg, MD, UNITED STATES  
Evans, Krista L., Germantown, MD, UNITED STATES  
PI US 2003144230 A1 20030731  
AI US 2002-200879 A1 20020723 (10)  
RLI Continuation of Ser. No. US 2001-911569, filed on 23 Jul 2001, PENDING  
Continuation of Ser. No. US 1998-39780, filed on 16 Mar 1998, GRANTED,  
Pat. No. US 6376248 Continuation-in-part of Ser. No. US 1997-818200,  
filed on 14 Mar 1997, GRANTED, Pat. No. US 6051429 Continuation-in-part  
of Ser. No. US 1996-658130, filed on 4 Jun 1996, GRANTED, Pat. No. US  
5736392 Continuation-in-part of Ser. No. US 1995-477354, filed on 7 Jun  
1995, ABANDONED

DT Utility  
FS APPLICATION  
LREP GREENLEE WINNER AND SULLIVAN P C, 5370 MANHATTAN CIRCLE, SUITE 201,  
BOULDER, CO, 80303  
CLMN Number of Claims: 77  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Page(s)  
LN.CNT 4805

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions useful for transfecting eukaryotic cells comprising nucleic acid complexes with peptides, wherein the peptide is optionally covalently coupled to a nucleic acid-binding group, and cationic lipids or dendrimers as transfection agents. The invention also provides transfection compositions in which a peptide is covalently linked to the transfection agent (lipid, cationic lipid or **dendrimer**). Inclusion of peptides or modified-peptides in transfection compositions or covalent attachment of peptides to transfection agents results in enhanced transfection efficiency. Methods for the preparation of transfection compositions and methods of using these transfection compositions as intracellular delivery agents and extracellular targeting agents are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 16 USPATFULL on STN  
AN 2003:100063 USPATFULL  
TI Peptide-enhanced transfections  
IN Hawley-Nelson, Pamela, Silver Spring, MD, UNITED STATES  
Lan, Jianqing, Germantown, MD, UNITED STATES  
Shih, PoJen, Columbia, MD, UNITED STATES  
Jessee, Joel A., Mt. Airy, MD, UNITED STATES  
Schifferli, Kevin P., Germantown, MD, UNITED STATES  
Gebeyehu, Gulilat, Silver Spring, MD, UNITED STATES  
Ciccarone, Valentina C., Gaithersburg, MD, UNITED STATES  
Evans, Krista L., Germantown, MD, UNITED STATES  
PA Life Technologies, Inc. (U.S. corporation)  
PI US 2003069173 A1 20030410  
AI US 2001-911569 A1 20010723 (9)  
RLI Continuation of Ser. No. US 1998-39780, filed on 16 Mar 1998, PENDING  
DT Utility  
FS APPLICATION  
LREP GREENLEE WINNER and SULLIVAN, P.C., Suite 201, 5370 Manhattan Circle,  
Boulder, CO, 80303  
CLMN Number of Claims: 77  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Page(s)  
LN.CNT 4787

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions useful for transfecting eukaryotic cells comprising nucleic acid complexes with peptides, wherein the peptide is optionally covalently coupled to a nucleic acid-binding group, and cationic lipids or dendrimers as transfection agents. The invention also provides transfection compositions in which a peptide is covalently linked to the transfection agent (lipid, cationic lipid or **dendrimer**). Inclusion of peptides or modified-peptides in transfection compositions or covalent attachment of peptides to transfection agents results in enhanced transfection efficiency. Methods for the preparation of transfection compositions and methods of using these transfection compositions as intracellular delivery agents and extracellular targeting agents are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 16 USPATFULL on STN  
AN 2002:228446 USPATFULL  
TI Dendrimeric support or carrier macromolecule  
IN Frechet, Jean J., Oakland, CA, UNITED STATES  
Ihre, Rolf H., Stockholm, SWEDEN  
PA The Regents of the University of California, Oakland, CA (U.S.  
corporation)  
PI US 2002123609 A1 20020905  
AI US 2001-963858 A1 20010925 (9)  
PRAI US 2000-236561P 20000929 (60)  
DT Utility  
FS APPLICATION  
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH  
FLOOR, SAN FRANCISCO, CA, 94111-3834  
CLMN Number of Claims: 48  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Page(s)  
LN.CNT 3331

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a family of dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and technological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 16 USPATFULL on STN  
AN 2002:88268 USPATFULL  
TI Peptide-enhanced transfections  
IN Hawley-Nelson, Pamela, Silver Spring, MD, United States  
Lan, Jianqing, Germantown, MD, United States  
Shih, PoJen, Columbia, MD, United States  
Jessee, Joel A., Mt. Airy, MD, United States  
Schifferli, Kevin P., Germantown, MD, United States  
Gebeyehu, Gulilat, Silver Spring, MD, United States  
Ciccarone, Valentina C., Gaithersburg, MD, United States  
Evans, Krista L., Germantown, MD, United States  
PA Life Technologies, Inc., Rockville, MD, United States (U.S. corporation)  
PI US 6376248 B1 20020423  
AI US 1998-39780 19980316 (9)  
RLI Continuation-in-part of Ser. No. US 1997-818200, filed on 14 Mar 1997,  
now patented, Pat. No. US 6051429, issued on 8 Apr 2000  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Brusca, John S.  
LREP Greenlee, Winner and Sullivan, P.C.  
CLMN Number of Claims: 30  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)  
LN.CNT 4698

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions useful for transfecting eukaryotic cells comprising nucleic acid complexes with peptides, wherein the peptide is optionally covalently coupled to a nucleic acid-binding group, and cationic lipids or dendrimers as transfection agents. The invention also provides transfection compositions in which a peptide is covalently linked to the transfection agent (lipid, cationic lipid or **dendrimer**). Inclusion of peptides or modified-peptides in transfection compositions or covalent attachment of peptides to transfection agents results in enhanced transfection efficiency. Methods for the preparation of transfection compositions and methods of using these transfection compositions as intracellular delivery agents and extracellular targeting agents are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 16 USPATFULL on STN  
AN 2001:234992 USPATFULL  
TI Nanogel networks and biological agent compositions thereof  
IN Kabanov, Alexander V., Omaha, NE, United States  
Vinogradov, Sergey V., Omaha, NE, United States  
PA Supratek Pharma, Inc., Canada (non-U.S. corporation)  
PI US 6333051 B1 20011225  
AI US 1998-146651 19980903 (9)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Riley, Jezia  
LREP Mathews, Collins, Shepherd & Gould, P.A.  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2246

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Copolymer networks having at least one cross-linked polyamine polymer fragment and at least one nonionic water-soluble polymer fragment, and compositions thereof, having at least one suitable biological agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 16 USPATFULL on STN  
AN 2000:138043 USPATFULL

TI Combinatorial synthesis on soluble polyvalent supports having a discrete architecture  
IN Chapman, Kevin T., Scotch Plains, NJ, United States  
Hutchins, Steven M., Somerville, NJ, United States  
Kim, Ronald M., Monmouth Junction, NJ, United States  
Manna, Mahua, Woodbridge, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 6132953 20001017  
AI US 1997-884893 19970630 (8)  
PRAI US 1996-21033P 19960702 (60)  
US 1996-26012P 19960912 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Celsa, Bennett; Assistant Examiner: Ricigliano, Joseph W.  
LREP McGinnis, James L., Rose, David L.  
CLMN Number of Claims: 24  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to the use of a soluble polyvalent support for the preparation of combinatorial libraries of compounds. The resultant combinatorial libraries are useful in screening for biologically active moieties in the drug discovery process or in developing compounds with desired physical and chemical properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 16 USPATFULL on STN  
AN 2000:15299 USPATFULL  
TI Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders  
IN DeGrado, William Frank, Moylan, PA, United States  
Mousa, Shaker Ahmed, Lincoln University, PA, United States  
Sworin, Michael, Newark, DE, United States  
Barrett, John Andrew, West Groton, MA, United States  
Edwards, Scott David, Burlington, MA, United States  
Harris, Thomas David, Salem, NH, United States  
Rajopadhye, Milind, Westford, MA, United States  
Liu, Shuang, Chelmsford, MA, United States  
PA DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)  
PI US 6022523 20000208  
AI US 1997-999400 19971229 (8)  
RLI Continuation of Ser. No. US 1994-218861, filed on 28 Mar 1994, now patented, Pat. No. US 5879657 which is a continuation-in-part of Ser. No. US 1993-40336, filed on 30 Mar 1993, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Jameison, Fabian A.  
LREP Boudreaux, G. Jess, Vance, David H.  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 6906

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides novel radiopharmaceuticals that are radiolabeled cyclic compounds containing carbocyclic or heterocyclic ring systems which act as antagonists of the platelet glycoprotein IIb/IIIa complex; to methods of using said radiopharmaceuticals as imaging agents for the diagnosis of arterial and venous thrombi; to novel reagents for the preparation of said radiopharmaceuticals; and to kits comprising said reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 16 USPATFULL on STN  
AN 1999:30347 USPATFULL  
TI - Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders  
IN DeGrado, William Frank, Moylan, PA, United States  
Mousa, Shaker Ahmed, Lincoln University, PA, United States  
Sworin, Michael, Newark, DE, United States  
Barrett, John Andrew, West Groton, MA, United States  
Edwards, Scott David, Burlington, MA, United States  
Harris, Thomas David, Salem, NH, United States  
Rajopadhye, Milind, Westford, MA, United States  
Liu, Shuang, Chelmsford, MA, United States  
PA The Dupont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)  
PI US 5879657 19990309  
AI US 1994-218861 19940328 (8)  
RLI Continuation-in-part of Ser. No. US 1993-40336, filed on 30 Mar 1993, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Jones, Dameron  
LREP Boudreaux, Gerald J., Vance, David H.  
CLMN Number of Claims: 70  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 8395  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB This invention provides novel radiopharmaceuticals that are radiolabeled cyclic compounds containing carbocyclic or heterocyclic ring systems which act as antagonists of the platelet glycoprotein IIb/IIIa complex; to methods of using said radiopharmaceuticals as imaging agents for the diagnosis of arterial and venous thrombi; to novel reagents for the preparation of said radiopharmaceuticals; and to kits comprising said reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 16 USPATFULL on STN  
AN 97:47507 USPATFULL  
TI Preparation and use of immunoconjugates  
IN Hansen, Hans J., Mystic Island, NJ, United States  
Leung, Shui-on, Madison, NJ, United States  
Shevitz, Jerry, Livingston, NJ, United States  
Griffiths, Gary L., Morristown, NJ, United States  
Govindan, Seregulam V., Summit, NJ, United States  
PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)  
PI US 5635603 19970603  
AI US 1994-352715 19941205 (8)  
RLI Continuation-in-part of Ser. No. US 1993-162912, filed on 8 Dec 1993, now patented, Pat. No. US 5443953, issued on 22 Aug 1995  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Reeves, Julie E.  
LREP Foley & Lardner  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2541  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to immunoconjugates comprising an antibody fragment which is covalently bound to a diagnostic or therapeutic principle through a carbohydrate moiety in the light chain variable region of the antibody fragment. The invention also relates to immunoconjugates comprising an antibody moiety that is an intact antibody containing a glycosylation site in the light chain variable domain which has been introduced into the antibody by mutating the nucleotide sequence encoding the light chain. The resultant immunoconjugates retain the immunoreactivity of the antibody fragment or

intact antibody, and target the diagnostic or therapeutic principle to a target tissue where the diagnostic or therapeutic effect is realized. Thus, the invention contemplates the use of such immunoconjugates for diagnosis and immunotherapy. The invention further relates to methods for preparing such immunoconjugates.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>